Amevive® (Alefacept) - A - Detailing from Skin Therapy Letter


Amevive® (Alefacept)







  • Moderate to severe disease (>10% of body surface area involved)
  • Patients who are candidates for phototherapy or systemic therapy
  • Those who are uncomfortable with or intolerant to the side effects of other therapies
  • Patients who are dissatisfied or are having inadequate response to their current treatment
  • < 10% of body surface area involved: patients whose psoriasis has a very significant impact on their Quality of Life

Next:   Dosing